Cargando…

Challenge in the Discovery of New Drugs: Antimicrobial Peptides against WHO-List of Critical and High-Priority Bacteria

Bacterial resistance has intensified in recent years due to the uncontrolled use of conventional drugs, and new bacterial strains with multiple resistance have been reported. This problem may be solved by using antimicrobial peptides (AMPs), which fulfill their bactericidal activity without developi...

Descripción completa

Detalles Bibliográficos
Autores principales: Roque-Borda, Cesar Augusto, da Silva, Patricia Bento, Rodrigues, Mosar Corrêa, Azevedo, Ricardo Bentes, Di Filippo, Leonardo, Duarte, Jonatas L., Chorilli, Marlus, Festozo Vicente, Eduardo, Pavan, Fernando Rogério
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224320/
https://www.ncbi.nlm.nih.gov/pubmed/34064302
http://dx.doi.org/10.3390/pharmaceutics13060773
_version_ 1783711863301734400
author Roque-Borda, Cesar Augusto
da Silva, Patricia Bento
Rodrigues, Mosar Corrêa
Azevedo, Ricardo Bentes
Di Filippo, Leonardo
Duarte, Jonatas L.
Chorilli, Marlus
Festozo Vicente, Eduardo
Pavan, Fernando Rogério
author_facet Roque-Borda, Cesar Augusto
da Silva, Patricia Bento
Rodrigues, Mosar Corrêa
Azevedo, Ricardo Bentes
Di Filippo, Leonardo
Duarte, Jonatas L.
Chorilli, Marlus
Festozo Vicente, Eduardo
Pavan, Fernando Rogério
author_sort Roque-Borda, Cesar Augusto
collection PubMed
description Bacterial resistance has intensified in recent years due to the uncontrolled use of conventional drugs, and new bacterial strains with multiple resistance have been reported. This problem may be solved by using antimicrobial peptides (AMPs), which fulfill their bactericidal activity without developing much bacterial resistance. The rapid interaction between AMPs and the bacterial cell membrane means that the bacteria cannot easily develop resistance mechanisms. In addition, various drugs for clinical use have lost their effect as a conventional treatment; however, the synergistic effect of AMPs with these drugs would help to reactivate and enhance antimicrobial activity. Their efficiency against multi-resistant and extensively resistant bacteria has positioned them as promising molecules to replace or improve conventional drugs. In this review, we examined the importance of antimicrobial peptides and their successful activity against critical and high-priority bacteria published in the WHO list.
format Online
Article
Text
id pubmed-8224320
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82243202021-06-25 Challenge in the Discovery of New Drugs: Antimicrobial Peptides against WHO-List of Critical and High-Priority Bacteria Roque-Borda, Cesar Augusto da Silva, Patricia Bento Rodrigues, Mosar Corrêa Azevedo, Ricardo Bentes Di Filippo, Leonardo Duarte, Jonatas L. Chorilli, Marlus Festozo Vicente, Eduardo Pavan, Fernando Rogério Pharmaceutics Review Bacterial resistance has intensified in recent years due to the uncontrolled use of conventional drugs, and new bacterial strains with multiple resistance have been reported. This problem may be solved by using antimicrobial peptides (AMPs), which fulfill their bactericidal activity without developing much bacterial resistance. The rapid interaction between AMPs and the bacterial cell membrane means that the bacteria cannot easily develop resistance mechanisms. In addition, various drugs for clinical use have lost their effect as a conventional treatment; however, the synergistic effect of AMPs with these drugs would help to reactivate and enhance antimicrobial activity. Their efficiency against multi-resistant and extensively resistant bacteria has positioned them as promising molecules to replace or improve conventional drugs. In this review, we examined the importance of antimicrobial peptides and their successful activity against critical and high-priority bacteria published in the WHO list. MDPI 2021-05-21 /pmc/articles/PMC8224320/ /pubmed/34064302 http://dx.doi.org/10.3390/pharmaceutics13060773 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Roque-Borda, Cesar Augusto
da Silva, Patricia Bento
Rodrigues, Mosar Corrêa
Azevedo, Ricardo Bentes
Di Filippo, Leonardo
Duarte, Jonatas L.
Chorilli, Marlus
Festozo Vicente, Eduardo
Pavan, Fernando Rogério
Challenge in the Discovery of New Drugs: Antimicrobial Peptides against WHO-List of Critical and High-Priority Bacteria
title Challenge in the Discovery of New Drugs: Antimicrobial Peptides against WHO-List of Critical and High-Priority Bacteria
title_full Challenge in the Discovery of New Drugs: Antimicrobial Peptides against WHO-List of Critical and High-Priority Bacteria
title_fullStr Challenge in the Discovery of New Drugs: Antimicrobial Peptides against WHO-List of Critical and High-Priority Bacteria
title_full_unstemmed Challenge in the Discovery of New Drugs: Antimicrobial Peptides against WHO-List of Critical and High-Priority Bacteria
title_short Challenge in the Discovery of New Drugs: Antimicrobial Peptides against WHO-List of Critical and High-Priority Bacteria
title_sort challenge in the discovery of new drugs: antimicrobial peptides against who-list of critical and high-priority bacteria
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224320/
https://www.ncbi.nlm.nih.gov/pubmed/34064302
http://dx.doi.org/10.3390/pharmaceutics13060773
work_keys_str_mv AT roquebordacesaraugusto challengeinthediscoveryofnewdrugsantimicrobialpeptidesagainstwholistofcriticalandhighprioritybacteria
AT dasilvapatriciabento challengeinthediscoveryofnewdrugsantimicrobialpeptidesagainstwholistofcriticalandhighprioritybacteria
AT rodriguesmosarcorrea challengeinthediscoveryofnewdrugsantimicrobialpeptidesagainstwholistofcriticalandhighprioritybacteria
AT azevedoricardobentes challengeinthediscoveryofnewdrugsantimicrobialpeptidesagainstwholistofcriticalandhighprioritybacteria
AT difilippoleonardo challengeinthediscoveryofnewdrugsantimicrobialpeptidesagainstwholistofcriticalandhighprioritybacteria
AT duartejonatasl challengeinthediscoveryofnewdrugsantimicrobialpeptidesagainstwholistofcriticalandhighprioritybacteria
AT chorillimarlus challengeinthediscoveryofnewdrugsantimicrobialpeptidesagainstwholistofcriticalandhighprioritybacteria
AT festozovicenteeduardo challengeinthediscoveryofnewdrugsantimicrobialpeptidesagainstwholistofcriticalandhighprioritybacteria
AT pavanfernandorogerio challengeinthediscoveryofnewdrugsantimicrobialpeptidesagainstwholistofcriticalandhighprioritybacteria